Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant ...

A TOR-targeting cancer drug unexpectedly extends yeast lifespan through a newly discovered metabolic feedback loop.

HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful ...

Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) ...

Researchers have identified a protein responsible for activating RAS signaling pathways in aggressive tumors, offering a ...

Oncolytics Biotech Inc. (NASDAQ: ONCY) has secured FDA alignment on its pivotal Phase 3 study design for pelareorep in ...

A next-generation drug tested in yeast was found to extend lifespan and slow aging by influencing a major growth-control pathway. Researchers also uncovered an unexpected role for agmatinases, enzymes ...

Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in ...

Discover why Terns Pharmaceuticals, Inc. stock is up 770% YTD with strong CML drug data and major upcoming milestones. Click ...

A research group led by Prof. Zhang Peng from the Institute of Biophysics of the Chinese Academy of Sciences has revealed how the human brain resolves perceptual conflicts and generates conscious ...

Results from SCOPE to date have enabled Scancell to select Immunobody iSCIB1+, administered needle-free intramuscularly, for further development in patients with selected human leukocyte antigen (HLA) ...